Celebrex-mas: Pfizer Gets Early Present With Juvenile RA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will have to conduct a long-term registry to further evaluate safety concerns with the COX-2 inhibitor, including cardiovascular events.
You may also be interested in...
Celebrex Adverse Events On FDA Pediatrics Committee Agenda In Late March
Celebrex adverse events will be reviewed by FDA Pediatrics Advisory Committee March 25; seven other drugs also on agenda.
Celebrex Adverse Events On FDA Pediatrics Committee Agenda In Late March
Celebrex adverse events will be reviewed by FDA Pediatrics Advisory Committee March 25; seven other drugs also on agenda.
Validity of Celebrex Patents Upheld In Court, Barring Generics Until 2015
ANDA filer Teva says it will appeal a federal court decision over the COX-2 inhibitor.